While there are many clinical trials exploring the effect of various novel agents in combination with lenalidomide-dexamethasone therapy in multiple myeloma (MM), patients who are lenalidomide refractory would not be eligible for these studies. Ajai Chari, MD, PhD, of Mount Sinai School of Medicine, New York, NY, presented results from a subgroup analysis of the MMY1001 trial (NCT01998971) at the 2018 American Society of Oncology (ASCO) Annual Meeting, held in Chicago, IL, which saw lenalidomide refractory MM patients given the combination of daratumumab plus carfilzomib-dexamethasone. Prof. Chari discusses the data from this trial, which showed lenalidomide refractory patients had a similar response rate as the control patients, and that these patients obtained more durable progression-free survival statuses than those in other similar studies. He finally discusses the benefits of giving initial daratumumab doses over a two-day period instead of one.
MMY1001 subgroup: daratumumab-Kd in lenalidomide refractory MM
